Evaluating and Staging the Patient with Breast Cancer

Breast Cancer

Volumn , Issue , 2005, Pages 309-318

  Huston, Tara L ^a,b   Osborne, Michael P ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c STRANG CANCER PREVENTION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882507529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06634-4.50022-4     Document Type: Chapter

References (55)

1. Patterson R The Treatment of Malignant Disease by Radium and X-rays 1948, Edward Arnold, London.
2. Haagensen CD, Stout AP Carcinoma of the breast: Criteria of operability. Ann Surg 1943, 118:859-870.
3. http://training.seer.cancer.gov.
4. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003, 83(4):803-819.
5. American Joint Committee on Cancer. Manual for Staging Breast Cancer 1988, JB Lippincott, Philadelphia. 3rd ed. O.H. Beahrs, D.E. Henson, R.V.P. Hutter (Eds.).
6. UICC TNM Classification of Malignant Tumors 1987, Springer-Verlag, Berlin. 4th ed. P. Hermanek, L.H. Sobin (Eds.).
7. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual 2002, Springer-Verlag, New York. 6th ed.
8. Shin SJ, Osborne MP, Moore A, et al. Determination of size in invasive breast carcinoma: Pathologic considerations and clinical implications. Am J Clin Pathol 2000, 113(5 Suppl 1):S19-S29.
9. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 1996, 88:1652-1664.
10. Fisher B, Slack NH, Bross IDJ, et al. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969, 24:1071-1080.
11. Koscielny S, Tubiana M, Le MG, et al. Breast cancer: Relationship between the size of the primary and the probability of metastatic dissemination. Br J Cancer 1984, 49:709-715.
12. Andea AA, Wallis T, Newman LA, et al. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002, 94(5):1383-1390.
13. Cady M, Stone MD, Schuler JG, et al. The new era in breast cancer: Invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996, 131:30-38.
14. Brower ST, Cunningham JD, Tartter PI Staging and assessing prognosis in breast cancer. Breast Cancer 1997, 275. WB Saunders, Philadelphia. D. Rose (Ed.).
15. Payne WS, Taylor WF, Khonsari S, et al. Surgical treatment of breast cancer: Trends and factors affecting survival. Arch Surg 1970, 101:105-113.
16. Ferguson DJ, Meier P, Karrison T, et al. Staging of breast cancer and survival rates: An assessment based on 50 years of experience with radical mastectomy. JAMA 1982, 248:1337-1341.
17. Giuliano AE, Kirgan DM, Guenther JM, Morton DL Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220(3):391-398.
18. O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998, 186(4):423-427.
19. Dowlatshahi K, Fan M, Snider HC, Habib FA Lymph node micro-metastases from breast carcinoma: Reviewing the dilemma. Cancer 1997, 80(7):1188-1197.
20. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995, 222(3):394-399.
21. Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999, 17(8):2334-2340.
22. Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001, 181(4):313-318.
23. Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, et al. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001, 193(5):547-555.
24. Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol 2001, 19(3):628-633.
25. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer dramatically affect stage-specific survival. J Clin Oncol 2003, 21(17):3244-3248.
26. Elston CW, Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410.
27. Ciatto S, Pacini P, Azzini V, et al. Preoperative staging of primary breast cancer. A multicentric study. Cancer 1988, 61(5):1038-1040.
28. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001, 22(8):875-879.
29. Chan Y, Chan K, Lam W, et al. Comparison of whole body MRI and radioisotope bone scintigram for skeletal metastases detection. Chin Med J (Engl) 1997, 110(6):485-489.
30. Moskovic E, Parsons C, Baum M Chest radiography in the management of breast cancer. Br J Radiol 1992, 65(769):30-32.
31. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002, 23(9):857-864.
32. Clark CP, Foreman ML, Peters GN, et al. Efficacy of preoperative liver function tests and ultrasound in detecting hepatic metastasis in carcinoma of the breast. Surg Gynecol Obstet 1988, 167(6):510-514.
33. Eberhardt SC, Choi PH, Bach AM, et al. Utility of sonography for small hepatic lesions found on computed tomography in patients with cancer. J Ultrasound Med 2003, 22(4):335-343.
34. Reinig JW, Dwyer AJ, Miller DL, et al. Liver metastasis detection: Comparative sensitivities of MR imaging and CT scanning. Radiology 1987, 162(1 Pt 1):43-47.
35. Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 2003, 89(2):284-290.
36. Chang EL, Lo S Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003, 8(5):398-410.
37. Cote RJ, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991, 9(10):1749-1756.
38. Simmons R, Hoda S, Osborne M Bone marrow micrometastases in breast cancer patients. Am J Surg 2000, 180(4):309-312.
39. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342(8):525-533.
40. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996, 88(22):1652-1658.
41. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003, 21(18):3469-3478.
42. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992, 339(8785):71-85. Early Breast Cancer Trialists' Collaborative Group.
43. Crowe JP, Gordon NH, Hubay CA, et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1991, 173(4):273-278.
44. An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351(9114):1451-1467. Tamoxifen for early breast cancer.
45. Knight WA, Osborne CK, McGuire W Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 1980, 9:361-368.
46. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21(10):1973-1979.
47. Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993, 28(1):9-20.
48. Volpi A, De Paola F, Nanni O, et al. Prognostic significance of biologic markers in node-negative breast cancer patients: A prospective study. Breast Cancer Res Treat 2000, 63(3):181-192.
49. Volpi A, Nanni O, De Paola, et al. HER-2 expression and cell proliferation: Prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003, 21(14):2708-2712.
50. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8(1):103-112.
51. Sirvent JJ, Fortuno-Mar A, Olona M, Orti A Prognostic value of p53 protein expression and clinicopathological factors in infiltrating ductal carcinoma of the breast. A study of 192 patients. Histol Histopathol 2001, 16(1):99-106.
52. Folkman J The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995, 36(2):109-118.
53. Dickson RB, Lippman ME Growth factors in breast cancer. Endocr Rev 1995, 16(5):559-589.
54. Laban C, Bustin SA, Jenkins PJ The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003, 14(1):28-34.
55. Smith TJ, Davidson NE, Schapira DV, et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999, 17(3):1080-1082.